Core Viewpoint - Investors in Biohaven Ltd. have the opportunity to lead a securities fraud class action lawsuit due to alleged misrepresentations regarding the company's drug candidates and their regulatory prospects [1][2]. Summary by Relevant Sections Lawsuit Details - The lawsuit alleges that from March 24, 2023, to May 14, 2025, Biohaven's management failed to disclose critical information about the regulatory prospects of its drug, troriluzole, for treating SCA, and the sufficiency of the data submitted for its approval [2] - It is claimed that the efficacy and clinical prospects of another drug, BHV-7000, for treating bipolar disorder were also overstated [2] - The lawsuit suggests that the eventual revelation of these issues would significantly negatively impact Biohaven's business and financial condition [2] - Defendants' positive statements regarding the company's operations and prospects were allegedly materially misleading and lacked a reasonable basis [2]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Biohaven Ltd. regarding a class action lawsuit due to alleged misleading statements about the company's product candidates and their regulatory prospects [1][2]. Group 1: Allegations - The complaint alleges that during the class period from March 24, 2023, to May 14, 2025, Biohaven's statements regarding the regulatory prospects of its product candidate, troriluzole, were overstated [1]. - It is claimed that the efficacy and clinical prospects of BHV-7000 as a treatment for bipolar disorder were also overstated [1]. - The revelations of these overstated claims are likely to have a significant negative impact on Biohaven's business and financial condition [1]. Group 2: Class Action Details - Shareholders who purchased shares of BHVN during the specified class period are encouraged to register for the class action, with a deadline for lead plaintiff appointment set for September 12, 2025 [2]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the lifecycle of the case [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit and illegal business practices [3]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements that artificially inflate stock prices [3].

Core Viewpoint - A class action lawsuit has been filed against Biohaven Ltd. and certain officers for alleged violations of federal securities laws during the Class Period from March 24, 2023, to May 14, 2025, seeking damages for affected investors [1][6]. Company Overview - Biohaven is a biopharmaceutical company focused on developing therapies in immunology, neuroscience, and oncology, with notable product candidates including troriluzole for spinocerebellar ataxia and BHV-7000 for bipolar disorder [3]. Regulatory Developments - In May 2022, a Phase 3 trial for troriluzole failed to meet its primary endpoint, yet the company continued to promote its regulatory prospects based on post-hoc analyses [4]. - Biohaven submitted a New Drug Application (NDA) for troriluzole to the FDA in May 2023, and the European Medicines Agency (EMA) accepted its Marketing Authorization Application (MAA) in October 2023 [5]. Allegations of Misleading Statements - Throughout the Class Period, Biohaven's executives allegedly made materially false and misleading statements regarding the company's business and the regulatory prospects of its products, particularly regarding troriluzole and BHV-7000 [6]. Stock Price Reactions - Following the FDA's rejection of the troriluzole NDA on July 27, 2023, Biohaven's stock price dropped by $5.38, or 22.61%, closing at $18.42 [7]. - On March 3, 2025, after disclosing disappointing data for BHV-7000, the stock fell by $5.12, or 13.77%, to $32.06 [9]. - Reports of the withdrawal of the troriluzole MAA led to a stock price decline of $3.56, or 15.21%, closing at $19.84 on April 25, 2025 [10]. - On May 14, 2025, the announcement of an extended review period for the troriluzole NDA resulted in a further stock price drop of $3.84, or 19.53%, to $15.82 [11].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Biohaven Ltd. securities during the specified class period of the upcoming lead plaintiff deadline on September 12, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Biohaven securities between March 24, 2023, and May 14, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the September 12, 2025 deadline [2]. - The lawsuit claims that throughout the class period, Biohaven made false and misleading statements regarding the regulatory prospects of its drug troriluzole and its efficacy for treating bipolar disorder, which negatively impacted the company's business and financial condition [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company at the time [3]. - The firm has been ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [3]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [3].

NEW YORK, July 25, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Biohaven Ltd. ("Biohaven Ltd." or the "Company") (NYSE: BHVN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Biohaven Ltd. investors who were adversely affected by alleged securities fraud between March 24, 2023 and May 14, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/biohaven-ltd-lawsuit-sub ...

Core Viewpoint - Class action lawsuits have been filed against several publicly-traded companies, alleging misleading statements and failure to disclose critical information that may have impacted shareholders' investments [1]. Group 1: Hims & Hers Health, Inc. (NYSE: HIMS) - The class period for Hims & Hers Health, Inc. is from April 29, 2025, to June 23, 2025, with a lead plaintiff deadline of August 25, 2025 [2]. - Allegations include deceptive promotion and selling of illegitimate versions of Wegovy, risking patient safety, and potential termination of collaboration with Novo Nordisk [2]. Group 2: iRobot Corporation (NASDAQ: IRBT) - The class period for iRobot Corporation is from January 29, 2024, to March 11, 2025, with a lead plaintiff deadline of September 5, 2025 [3]. - Allegations state that iRobot overstated the effectiveness of its Restructuring Plan post-Amazon Acquisition, raising doubts about its ability to operate profitably as a standalone company [3]. Group 3: Centene Corporation (NYSE: CNC) - The class period for Centene Corporation is from December 12, 2024, to June 30, 2025, with a lead plaintiff deadline of September 8, 2025 [4]. - Allegations include lower-than-expected enrollment and increased market morbidity affecting over two-thirds of Centene's marketplace share, leading to misleading statements about the company's prospects [4]. Group 4: Biohaven Ltd. (NYSE: BHVN) - The class period for Biohaven Ltd. is from March 24, 2023, to May 14, 2025, with a lead plaintiff deadline of September 12, 2025 [5]. - Allegations involve overstated regulatory prospects for treatments and potential negative impacts on Biohaven's business and financial condition once the truth is revealed [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Biohaven Ltd. due to allegations of violations of federal securities laws, particularly concerning misleading statements about the company's drug candidates and their regulatory prospects [3][5]. Group 1: Legal Investigation and Class Action - The law firm is encouraging investors who suffered losses exceeding $50,000 in Biohaven between March 24, 2023, and May 14, 2025, to contact them for discussing legal options [1]. - A federal securities class action has been filed against Biohaven, with a deadline of September 12, 2025, for investors to seek the role of lead plaintiff [3][7]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. Group 2: Allegations Against Biohaven - The complaint alleges that Biohaven and its executives made false and misleading statements regarding the regulatory prospects of the drug troriluzole for treating spinocerebellar ataxia (SCA) and the efficacy of BHV-7000 for bipolar disorder [5]. - The allegations suggest that the overstated claims about these drugs' prospects could significantly negatively impact Biohaven's business and financial condition once revealed [5]. Group 3: Stock Price Impact - Following a press release on May 14, 2025, regarding the extension of the PDUFA date for the troriluzole NDA, Biohaven's stock price fell by $3.84 per share, or 19.53%, closing at $15.82 per share on May 15, 2025 [6].

NEW YORK, July 25, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Biohaven Ltd. ("Biohaven Ltd." or the "Company") (NYSE: BHVN) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Biohaven Ltd. investors who were adversely affected by alleged securities fraud between March 24, 2023 and May 14, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/biohaven-ltd-lawsuit-submissio ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Biohaven Ltd. securities during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The class period for the Biohaven securities is from March 24, 2023, to May 14, 2025, and the lead plaintiff deadline is September 12, 2025 [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must act by the lead plaintiff deadline to represent other class members [2] Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions [3] - Rosen Law Firm has achieved significant settlements in the past, including the largest securities class action settlement against a Chinese company at the time [3] - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [3] Group 3: Case Allegations - The lawsuit alleges that Biohaven made false and misleading statements regarding the regulatory prospects of its drug, troriluzole, and its efficacy for treating bipolar disorder [4] - It is claimed that the overstated claims about the drug's prospects likely had a significant negative impact on Biohaven's business and financial condition [4] - The lawsuit asserts that once the true details were revealed, investors suffered damages due to the misleading public statements [4]

NEW YORK, July 24, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Biohaven Ltd. (NYSE: BHVN). Shareholders who purchased shares of BHVN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/biohaven-ltd-loss-submission-form/?id=157781&from=3 CLASS PERIOD: March 24, 2023 to Ma ...